The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes
Open accessAbstract
BACKGROUND: We investigated whether intensive glycemic control, combination therapy for dyslipidemia, and intensive blood-pressure control would limit the progression of diabetic retinopathy in persons with type 2 diabetes. Previous data suggest that these systemic factors may be important in the development and progression of diabetic retinopathy. METHODS: In a randomized trial, we enrolled 10,251 participants with type 2 diabetes who were at high risk for cardiovascular disease to receive either intensive or standard treatment for glycemia (target glycated hemoglobin level, <6.0% or 7.0 to 7.9%, respectively) and also for dyslipidemia (160 mg daily of fenofibrate plus simvastatin or placebo plus simvastatin) or for systolic blood-pressure control (target, <120 or <140 mm Hg). A subgroup of 2856 participants was evaluated for the effects of these interventions at 4 years on the progression of diabetic retinopathy by 3 or more steps on the Early Treatment Diabetic Retinopathy Study Severity Scale (as assessed from seven-field stereoscopic fundus photographs, with 17 possible steps and a higher number of steps indicating greater severity) or the development of diabetic retinopathy necessitating laser photocoagulation or vitrectomy. RESULTS: At 4 years, the rates of progression of diabetic retinopathy were 7.3% with intensive glycemia treatment, versus 10.4% with standard therapy (adjusted odds ratio, 0.67; 95% confidence interval [CI], 0.51 to 0.87; P=0.003); 6.5% with fenofibrate for intensive dyslipidemia therapy, versus 10.2% with placebo (adjusted odds ratio, 0.60; 95% CI, 0.42 to 0.87; P=0.006); and 10.4% with intensive blood-pressure therapy, versus 8.8% with standard therapy (adjusted odds ratio, 1.23; 95% CI, 0.84 to 1.79; P=0.29). CONCLUSIONS: Intensive glycemic control and intensive combination treatment of dyslipidemia, but not intensive blood-pressure control, reduced the rate of progression of diabetic retinopathy. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov numbers, NCT00000620 for the ACCORD study and NCT00542178 for the ACCORD Eye study.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary composite major CV outcomes (nonfatal MI, nonfatal stroke or death from CV causes) were not reduced significantly in ACCORD (hazard ratio [HR] 0.90, p=0.16).”
From Targets for Glycemic Control (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with type 2 diabetes, an A1C ≤6.5% may be targeted to reduce the risk of CKD [Grade A, Level 1A (23)] and retinopathy [Grade A, Level 1A (21)], if they are assessed to be at low risk of hypoglycemia based on class of antihyperglycemic medication(s) utilized and the person's characteristics [Grade D, Consensus].”
From Targets for Glycemic Control (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The UK Prospective Diabetes Study randomly assigned 4209 patients with newly diagnosed type 2 diabetes to receive conventional (primarily diet) vs intensive (insulin, sulfonylurea, or, if overweight, metformin) treatment, with mean attained HbA1C of 7.9% vs 7.0%, respectively.36,37”
From Diagnosis and Treatment of Type 2 Diabetes in Adults (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Other options that can stabilize retinopathy include lifestyle intervention or bariatric surgery in persons with T2D or physical activity in persons with T1D.524–527”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [527]
Experimental — accuracy not yet measuredIn the citing paper
“Fenofibrate reduces the progression of diabetic retinopathy.413,414”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [414]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Self-citationStearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 4,803
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,023
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Self-citation
Research works printed but not linked: 4
- Davis MD, 1998, Invest Ophthalmol Vis Sci, 39, 233
- Cullen JF, 1964, Trans Ophthalmol Soc U K, 84, 281
- The ACCORD Study Group, 2007, Am J Cardiol, 99, 21i
- Ismail-Beigi F, 2010, Lancet, 375, 26
Cited by
Sorted by citations
Items 701–800 of 1,000
Hou, T., Li, M., Lin, H., Zhao, Z., Lu, J., Wang, T., Xu, Y., Wang, W., Bi, Y., Ning, G., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac354 · Cited by 11
Garberg, G., Lövestam‐Adrian, M., Nasic, S., & Boström, K. B. (2014) · International Ophthalmology · doi:10.1007/s10792-014-9976-y · Cited by 12
Update on Glycemic Control for the Treatment of Diabetic Kidney Disease
Nadkarni, G. N., Yacoub, R., & Coca, S. G. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0612-7 · Cited by 12
Ding, Y., Xu, H., Li, L., Yuan, Y., & Xu, Y. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.12.024 · Cited by 12
Madsen, L. R., Bek, T., & Richelsen, B. (2018) · Diabetic Medicine · doi:10.1111/dme.13876 · Cited by 13
Treat to Target in Axial Spondyloarthritis
Liew, J. W., & Dubreuil, M. (2020) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2020.01.011 · Cited by 12
Eye Outcomes in Veteran Affairs Diabetes Trial (VADT) After 17 Years
Azad, N., Agrawal, L., Bahn, G., Emanuele, N., Reaven, P. D., Hayward, R. A., Reda, D. J., & the VADT Study Group (2021) · Diabetes Care · doi:10.2337/dc20-2882 · Cited by 13
Mixed messages on systemic therapies for diabetic retinopathy
Lim, L. S., Liew, G., Cheung, N., Mitchell, P. L. R., & Wong, T. Y. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61984-8 · Cited by 12
Lu, V. I., Patnaik, J. L., Scott, R. A., Lynch, A. M., Smith, J. M., Mandava, N., & Manoharan, N. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.9.8 · Cited by 14
Wang, Y., Lu, J., Ni, J., Wang, M., Shen, Y., Lu, W., Zhu, W., Bao, Y., & Zhou, J. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3639 · Cited by 11
Jeong, H., Maatouk, C. M., Russell, M. W., & Singh, R. P. (2024) · Eye · doi:10.1038/s41433-024-03022-3 · Cited by 11
Mahapatro, A., Bozorgi, A., Obulareddy, S. U. J., Jain, S. M., Korsapati, R. R., Kumar, A., Patel, K., Moghadam, S. S., Arya, A., Alotaibi, A. J., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002592 · Cited by 12
Watts, G. F., & Karpe, F. (2011) · Postgraduate Medical Journal · doi:10.1136/pgmj.2010.204990rep · Cited by 12
Dislipidemia aterogénica y riesgo residual. Estado de la cuestión en 2014
Núñez-Cortés, J. M., Pedro‐Botet, J., & Pintó, X. (2014) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2014.09.004 · Cited by 11
Mazzeo, A., Gai, C., Trento, M., Porta, M., & Beltramo, E. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01565-x · Cited by 13
Lee, J. H., Kim, Y., Lee, Y.-C., Bang, W., & Seo, J. (2020) · Diabetes & vascular disease research · doi:10.1177/1479164120945910 · Cited by 9
Murakami, T., Kato, S., Shigeeda, T., Itoh, H., Komuro, I., Takeuchi, M., Yoshimura, N., & for the ophthalmology substudy of EMPATHY Investigators (2020) · Eye · doi:10.1038/s41433-020-01202-5 · Cited by 11
Lam, P. Y., Chow, S. C., Lam, W., Chow, L. L. W., & Fung, N. S. K. (2021) · Clinical ophthalmology · doi:10.2147/opth.s301317 · Cited by 12
Individualized Glycemic Goals for Older Adults Are a Moving Target
Pilla, S. J., Yazdi, Z. S., & Taylor, S. I. (2022) · Diabetes Care · doi:10.2337/dci22-0004 · Cited by 11
Diabetes Control Among Hispanics in the Action to Control Cardiovascular Risk in Diabetes Trial
Getaneh, A., Light, L. S., Brillon, D. J., Escandón, J. C., Felicetta, J. V., Evans, G. W., Lopez-Jimenez, C., Cuddihy, R. M., & Bigger, J. T. (2012) · Journal of General Internal Medicine · doi:10.1007/s11606-012-2131-4 · Cited by 11
Boussageon, R., Supper, I., Erpeldinger, S., Cucherat, M., Bejan‐Angoulvant, T., Kassaï, B., Cornu, C., & Gueyffier, F. (2013) · BMC Medical Research Methodology · doi:10.1186/1471-2288-13-107 · Cited by 12
Regional differences in the prevalence of diabetic retinopathy: a multi center study in Brazil
The Brazilian Type 1 Diabetes Study Group, Drummond, K. R. G., Malerbi, F. K., Morales, P. H., Mattos, T. C. L., Pinheiro, A. A., Mallmann, F., Perez, R. V., Leal, F. S. L., Melo, L. G. N., et al. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0319-4 · Cited by 11
Self-citationSabe, S. A., Feng, J., Liu, Y., Scrimgeour, L. A., Ehsan, A., & Sellke, F. W. (2018) · Surgery · doi:10.1016/j.surg.2018.03.007 · Cited by 11
Marchand, L., Luyton, C., & Bernard, A. (2020) · Diabetic Medicine · doi:10.1111/dme.14390 · Cited by 11
Cellular targets in diabetic retinopathy therapy
Rodríguez, M. L., Millán, I., & Ortega, Á. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i9.1442 · Cited by 12
Sociodemographic and Economic Factors in Outcomes of Tube Shunts for Neovascular Glaucoma
Moster, M. R., Shalaby, W. S., Arbabi, A., Myers, J. S., Razeghinejad, R., Katz, L. J., & Shukla, A. G. (2021) · JOURNAL OF CURRENT GLAUCOMA PRACTICE · doi:10.5005/jp-journals-10078-1303 · Cited by 11
Lipid lowering therapy in type 2 diabetes
Föger, B. (2011) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-011-0908-4 · Cited by 11
The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy
Treacy, M. P., & Hurst, T. P. (2012) · BMC Ophthalmology · doi:10.1186/1471-2415-12-46 · Cited by 11
Matthews, D. R. (2011) · BMJ Evidence-Based Medicine · doi:10.1136/ebm1155 · Cited by 11
Therapeutic Potential of Topical Fenofibrate Eyedrops in Diabetic Retinopathy and AMD Rat Models
Shen, Y. G. W. (2014) · Journal of Clinical & Experimental Ophthalmology · doi:10.4172/2155-9570.1000347 · Cited by 11
Zhou, J., Song, Z., Bai, L., Zhu, X.-R., Li, H., & Yang, J. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0497-y · Cited by 12
RetractedDiabetic retinopathy (treatment).
Mohamed, Q. A., Ross, A. H., & Chu, C. J. (2011) · Europe PMC (PubMed Central) · Cited by 11
Zhou, J., Zhu, X.-R., Zhao, W., Yin, L., Li, H., Qi, L., & Yang, J. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0140 · Cited by 11
RetractedA Clinical Conundrum: Intensifying Glycemic Control in the Presence of Advanced Diabetic Retinopathy
Ipp, E., & Kumar, M. (2021) · Diabetes Care · doi:10.2337/dci21-0029 · Cited by 12
Romero‐Aroca, P., Verges, R., Pascual-Fontanilles, J., Valls, A., Franch‐Nadal, J., Barrot, J., Mundet, X., Torre, A. L., Moreno, A., Sagarra-Alamo, R., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206674 · Cited by 15
Metabolic memory and diabetic retinopathy: Legacy of glycemia and possible steps into future
Sheemar, A., Bellala, K., Sharma, S. V., Sharma, S., Kaur, I., Rani, P. K., Sivaprasad, S., Narayan, K. M. V., Das, T., & Takkar, B. (2024) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_2563_23 · Cited by 11
Lolekha, P., Khovidhunkit, W., Deerochanawong, C., Thongtang, N., Boonyasirinant, T., Rattarasarn, C., Chutinet, A., Ophascharoensuk, V., Somlaw, N., Sitthisook, S., et al. (2024) · Asian Biomedicine · doi:10.2478/abm-2024-0033 · Cited by 13
Residual Vascular Risk in T2DM: The Next Frontier
Michel, P., Sylvie, A., & Michel, F. (2011) · InTech eBooks · doi:10.5772/22716 · Cited by 10
Photoreceptor responses to light in the pathogenesis of diabetic retinopathy
Majidi, S. P., & Rajagopal, R. (2020) · Visual Neuroscience · doi:10.1017/s0952523820000061 · Cited by 10
A Narrative Review of Retinopathy in Diabetic Patients
Gupta, S., & Thool, A. R. (2024) · Cureus · doi:10.7759/cureus.52308 · Cited by 13
Alshaman, R., Kolieb, E., El‐Sayed, R. M., Gouda, S. G., Alattar, A., Zaitone, S. A., Abdelmaogood, A. K. K., Elabbasy, L. M., Eltrawy, A. H., Sayd, F. Y., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12030552 · Cited by 12
Nuclear proteins and diabetic retinopathy: a review
Li, B., Hussain, W., Jiang, Z.-L., Wang, J., Hussain, S., Yasoob, T. B., Zhai, Y., Ji, X., & Dang, Y. (2024) · BioMedical Engineering OnLine · doi:10.1186/s12938-024-01258-4 · Cited by 11
Achievement of therapeutic targets in Mexican patients with diabetes mellitus
Lavalle-Gonzalez, F. J., Chiquete, E., de la Luz, J., Ochoa-Guzmán, A., Sánchez-Orozco, L. V., & Godínez-Gutiérrez, S. A. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.07.005 · Cited by 10
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial—Clinical Implications
Ismail‐Beigi, F. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.148288 · Cited by 10
Shaikh, M. A., Gillani, S., & Dur-E-Yakta (2010) · PubMed · Cited by 10
Stegemann, S., Riedl, R., & Sourij, H. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.11.066 · Cited by 10
Morello, C. M., Rotunno, T., Khoan, J., & Hirsch, J. D. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018776663 · Cited by 9
Woo, Y., Shin, J.-S., Shim, C. Y., Kim, J., Kim, B., Park, S., Chang, H., Hong, G., Ko, Y., Kang, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205006 · Cited by 11
Patients With Good Vision and Diabetic Macular Edema Involving the Center of the Macula
Chew, E. Y. (2019) · JAMA · doi:10.1001/jama.2019.5793 · Cited by 10
Haider, S., Sadiq, S. N., Lufumpa, E., Sihre, H. K., Tallouzi, M., Moore, D., Nirantharakumar, K., & Price, M. J. (2020) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2020-000579 · Cited by 11
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 10
Therapeutic potentials of agonist and antagonist of adenosine receptors in type 2 diabetes
Sanni, O., & Terre’Blanche, G. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09668-8 · Cited by 10
Incidence, progression and regression of diabetic retinopathy in a northeastern Chinese population
Zhong, L., Wen, L., Wang, Y., Li, D., Zhai, G., Moonasar, N., Wang, F., & Liang, Y. (2022) · British Journal of Ophthalmology · doi:10.1136/bjo-2022-321384 · Cited by 10
Diabetic Macular Oedema Guidelines: An Australian Perspective
Yuen, Y. S., Gilhotra, J. S., Dalton, M., Aujla, J., Mehta, H., Wickremasinghe, S. S., Uppal, G., Arnold, J., Chen, F. K., Chang, A., et al. (2023) · Journal of Ophthalmology · doi:10.1155/2023/6329819 · Cited by 10
The Epidemiology of Diabetic Retinopathy
Klein, R., & Klein, R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00045-x · Cited by 10
Inzucchi, S. E., & Sherwin, R. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00237-2 · Cited by 10
Chew, E. Y. (2015) · Endocrine · doi:10.1007/s12020-015-0553-6 · Cited by 10
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Not enough known about fenofibrate’s kidney effects in people with Type 2 diabetes
Jenkins, A. J., O'Connell, R. L., Januszewski, A. S., Webster, A. C., Davis, T. M. E., Jardine, M., Scott, R. S., Taskinen, M., & KEECH, A. C. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111612 · Cited by 9
Cui, Y., Poudel, S., Xu, N., Zhou, K., Cheng, R., Liang, W., Yuan, T., Zhao, L., Qin, C., Stevens, K. G., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.037 · Cited by 10
Precision Medicine for Diabetic Retinopathy: Integrating Genetics, Biomarkers, Lifestyle, and AI
Kaurich, C., Mahajan, N. S., & Bhatwadekar, A. D. (2025) · Genes · doi:10.3390/genes16091096 · Cited by 11
Maver, A., Hristovski, D., Rindflesch, T. C., & Peterlin, B. (2013) · BioMed Research International · doi:10.1155/2013/848952 · Cited by 9
Surowiec, P., Matejko, B., Kopka, M., Filemonowicz-Skoczek, A., Klupa, T., Cyganek, K., Romanowska‐Dixon, B., & Malecki, M. T. (2021) · Endocrine · doi:10.1007/s12020-021-02871-2 · Cited by 10
Hill, S., Mullins, P., Murphy, R., Schmiedel, O., Vaghefi, E., Ramke, J., & Squirrell, D. (2021) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000464 · Cited by 11
Nonproliferative and Proliferative Diabetic Retinopathy
Sun, J. K., & Aiello, L. P. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_24 · Cited by 11
Arndt, C., Leclercq, I., Nazeyrollas, P., Durlach, A., Ducasse, A., Movesayan, I., Socquard, E., Clavel, C., Malloy, M., Pullinger, C. R., et al. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.04.004 · Cited by 9
Statins for prevention of diabetic-related blindness: a new treatment option?
El-Azab, M. F., Mysona, B. A., & El‐Remessy, A. B. (2011) · Expert Review of Ophthalmology · doi:10.1586/eop.11.36 · Cited by 9
Current treatment strategies for age-related ocular conditions.
Akpek, E. K., & Smith, R. A. (2013) · PubMed · Cited by 9
Wan, Z., Cui, M., & Zhang, Y. (2021) · International Journal of Ophthalmology · doi:10.18240/ijo.2021.02.12 · Cited by 9
Barriers to Premarital Thalassemia Screening in Asia
Jaffar, N., Khan, L., Ahmed, U. I., Vistro, N. H., Khan, A., & Memon, M. Y. (2021) · World Family Medicine Journal/Middle East Journal of Family Medicine · doi:10.5742/mewfm.2021.94106 · Cited by 10
Bashir, M., Elhadd, T. A., Dabbous, Z., Gul, W., Salameh, O., Siddiqui, M., Almuhannadi, H., Petropoulos, I. N., Khan, A., Ponirakis, G., et al. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102241 · Cited by 11
Ngah, N. F., Aziz, R. A. B. A., Mohamed, S. O., Tarmidzi, N. A. A., Adnan, A., Asnir, Z. Z., Hussein, Z. B., Siew, H. F., Mohamed, M., Lodz, N. A., et al. (2022) · International Journal of Ophthalmology · doi:10.18240/ijo.2022.12.16 · Cited by 9
Lee, J. J., Hu, Z., Wang, Y. A., Nath, D., Liang, W., Cui, Y., Ma, J., & Duerfeldt, A. S. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00056 · Cited by 9
Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?
Watts, G. F., & Karpe, F. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.61 · Cited by 10
Diet and Supplements in the Prevention and Treatment of Eye Diseases
Mares, J. A., Millen, A. E., Lawler, T. P., & Blomme, C. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802928-2.00019-9 · Cited by 9
Complicaciones microvasculares de la diabetes
Pérez‐Pevida, B., Llavero, M., Gargallo, J., & Escalada, J. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.09.003 · Cited by 9
Semenkovich, C. F., Goldberg, A. C., & Goldberg, I. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00037-x · Cited by 14
The changing role of the endocrinologist in the care of patients with diabetic retinopathy
Porta, M., & Taulaigo, A. V. (2014) · Endocrine · doi:10.1007/s12020-013-0119-4 · Cited by 10
Rosolová, H., Dobiášová, M., Soška, V., Blaha, V., Češka, R., Nussbaumerová, B., Pelikánová, T., & Souček, M. (2014) · Cor et Vasa · doi:10.1016/j.crvasa.2014.01.003 · Cited by 10
Effects of Fenofibrate on Adiponectin Expression in Retinas of Streptozotocin-Induced Diabetic Rats
Hsu, Y.-J., Wang, L., Yang, W., Yang, C., & Yang, C.-H. (2014) · Journal of Diabetes Research · doi:10.1155/2014/540326 · Cited by 9
Non-proliferative Diabetic Retinopathy
Bandello, F. M., Lattanzio, R., Zucchiatti, I., & Petruzzi, G. (2014) · Springer eBooks · doi:10.1007/978-3-642-54503-0_2 · Cited by 9
Sun, W., Su, M., Zhuang, L., Ding, Y., Zhang, Q., & Lyu, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-66157-z · Cited by 8
Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations
Hamilton‐Craig, I. R., Kostner, K., Woodhouse, S. P., & Colquhoun, D. (2012) · International Journal of Evidence-Based Healthcare · doi:10.1111/j.1744-1609.2012.00275.x · Cited by 8
Vorobyeva, I. V. (2017) · Ophthalmology in Russia · doi:10.18008/1816-5095-2017-1-67-77 · Cited by 8
Yang, Z., Liu, Q., Wen, D., Yu, Z., Zheng, C., Gao, F., Chen, C., Hu, L., Shi, Y., Zhu, X., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1098638 · Cited by 11
Fan, K., Yu, L., Wu, Y., Zheng, L., Yang, X., Lin, J., Wang, M., Ye, Y., Lin, R., Chen, Q., et al. (2023) · Materials & Design · doi:10.1016/j.matdes.2023.112412 · Cited by 8
Velidakis, N., Stachteas, P., Gkougkoudi, E., Papadopoulos, C. E., & Kadoglou, N. P. E. (2024) · Pharmaceuticals · doi:10.3390/ph17050568 · Cited by 8
de Expertos, G. D. T. D. D. A. D. L. S. E. D. A. Y. G. E. (2017) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2016.12.001 · Cited by 8
Han, J. S., Kim, K., Jung, Y., Lee, J., Namgung, J., Lee, H., Suh, J., Hwang, G., & Lee, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-33058-x · Cited by 8
Hwang, H. S., Kim, J. Y., Oh, T. K., Chae, J. B., & Kim, D. Y. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e179 · Cited by 8
Liu, J., Wu, Y., Qi, J.-J., Yue, Z.-P., & Hu, C. (2021) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211040109 · Cited by 8
White, N. H., Pan, Q., Knowler, W. C., Schroeder, E. B., Dabelea, D., Chew, E. Y., Blodi, B., Goldberg, R. B., Pi-Sunyer, X., Darwin, C. H., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2417 · Cited by 7
Relationship Between Risk Factors and Macular Thickness in Patients with Early Diabetic Retinopathy
Wei, Q., Qiu, W., Liu, Q., & Jiang, Y. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s366348 · Cited by 8
Therapeutic roles of PPARα activation in ocular ischemic diseases.
Lee, D., Tomita, Y., Negishi, K., & Kurihara, T. (2023) · PubMed · doi:10.14670/hh-18-542 · Cited by 8
Iyer, S. S. R., Radhakrishnan, N. S., Roohipourmoallai, R., Guerin, C. M., Maylath, J., & Garson, N. K. (2023) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2023.100270 · Cited by 8
Kılıçkap, M., Kozluca, V., Tan, T. S., & Akbulut, İ. M. (2023) · Angiology · doi:10.1177/00033197231183229 · Cited by 9
Hermans, M. P. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000413 · Cited by 8
Evaluation of a journal club preparatory session on student confidence for a graded journal club
Gurney, M. K., Buckley, K. D., & Karr, S. (2019) · Currents in Pharmacy Teaching and Learning · doi:10.1016/j.cptl.2019.09.011 · Cited by 10
Katsuyama, A., Kusuhara, S., Asahara, S., Nakai, S., Mori, S., Matsumiya, W., Miki, A., Kurimoto, T., Imai, H., Kido, Y., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001120 · Cited by 8
Digital retinal imaging in a residency-based patient-centered medical home.
Newman, R. J., Cummings, D. M., Doherty, L., & Patel, N. R. (2012) · PubMed · Cited by 8
Metadata
- Authors
- The ACCORD Study Group and ACCORD Eye Study Group
- Corresponding author
- The ACCORD Study Group and ACCORD Eye Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-07-15
- Volume
- 363
- Issue
- 3
- Pages
- 233-244
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4026164
- OpenAlex
- W2219384223
- Semantic Scholar
- 9a607a3bfd9432a917f703d573fdaa1052647711
- Cited by
- 1,311
- References
- 36
- Citations by year
- 2026: 54 · 2025: 60 · 2024: 66 · 2023: 86 · 2022: 73 · 2021: 94 · 2020: 96 · 2019: 57 · 2018: 78 · 2017: 87 · 2016: 82 · 2015: 84 · 2014: 74 · 2013: 81 · 2012: 93
- FWCI
- 111.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Regeneron Pharmaceuticals
- Massachusetts Medical Society
- Omron Healthcare
- Bayer HealthCare
- Daiichi-Sankyo
- Novo Nordisk
- Servier
- National Institutes of Health (n01hc95183-23-0-0, n01hc95180-24-0-1, n01hc95184-24-0-1, n01hc95181-23-0-1, n01hc95182-23-0-1, Z99 EY999999, n01hc95178-28-0-1, n01hc95179-25-0-0)
- Centers for Disease Control and Prevention
- National Institute on Aging
- National Heart, Lung, and Blood Institute (N01- HC-95181, R01HL073030, N01 HC095184, N01-HC- 95180, N01-HC-95178, N01 HC095182, N01 HC095181, Y01 HC001010, N01-HC-095183, N01 HC095178, N01-HC-95184, N01HC95179, IAAY1-HC-1010, IAA #Y1-HC-9035, N01 HC095180, Y01 HC009035, N01‐HC‐95183, N01-HC-95182, N01 HC095179)
- National Eye Institute (ZIAEY000410)
- National Institute of Diabetes and Digestive and Kidney Diseases
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- diabetic retinopathy, retinopathy progression, type 2 diabetes, tight glycemic control, HbA1c, fenofibrate, simvastatin, dyslipidemia, blood pressure control, laser photocoagulation, vitrectomy, cardiovascular risk reduction, combination therapy, Early Treatment Diabetic Retinopathy Study
- MeSH terms
- Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Drug Therapy, Combination, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hyperglycemia, Hypertension, Hypoglycemic Agents, Cholesterol, LDL, Male, Middle Aged, Fenofibrate, Disease Progression, Simvastatin, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
